D.M. Zhu, G.Q. Chen
Cureport, Inc., United States
pp. 9 - 12
Keywords: liposome manufacturing, nanoparticles, drug delivery
Liposome-based drug delivery is one of the clinically advanced technologies for the treatment of human cancer and severe infectious disease.It improves pharmacokinetics, reduces toxicity, and enhances efficacy of the drugs. The complex manufacturing process, poor reproducibility, and low scalability of the traditional liposome making methods represent the huge obstacles in liposome manufacturing that dramatically limits the development and commercialization of liposomal drugs.To surmount those obstacles we recently invented nPortTM platform nanotechnology for liposome manufacturing. In nPortTM process, lipids solution(s)in a water-miscible organic solvent is mixed with aqueous solutions in a specially designed multi-port mixing chamber to form liposomes.The flowrate of the solutions is adjustable in the range of microliters to multi-liters per minute. The particle size, morphology, and product scales are controlled by altering processing temperature, concentration, pH, flowrate, the number and the geometry of the inlet/outlet ports. nPortTM technology brings unparalleled and powerful advantages to liposome development including: 1)robust scalability from micrograms for research to kilograms for commercialization; 2) precise particle size control in the range of 20-200 nm with monodisperse; 3)reliable reproducibility; 4)a platform for varieties of formulations, payloads and morphologies of liposomes; 5)fast and cost-saving. This presentation will highlight nPortTM Technology for liposome preparations.